PCOS & Weight: Insulin Resistance, Androgens and What Helps

PCOS: where weight and hormones intertwine

Polycystic ovary syndrome (PCOS) is the most common hormonal condition in women of reproductive age, and one in which weight and hormones reinforce each other directly. Two engines drive it — insulin resistance and androgen (male-hormone) excess — and each feeds the other, producing irregular or absent periods, difficulty conceiving, acne, excess hair growth (hirsutism) and difficulty losing weight.

PCOS is not caused by weight; lean women have it too. Excess weight amplifies the insulin resistance and the androgen excess, and losing weight can quiet that loop. PCOS is also a metabolic condition rather than a purely reproductive one, raising long-term risk of type 2 diabetes, fatty liver and cardiovascular disease. Attributing the syndrome to a woman's weight is inaccurate; treating it as a metabolic condition that weight partly influences is both accurate and useful. → Women's Health & Obesity · Obesity & Hormones

Insulin resistance: the engine underneath

Insulin resistance sits at the centre of PCOS for most, though not all, women. The body's cells respond poorly to insulin, so the pancreas makes more of it, and those high insulin levels:

• promote fat storage and blunt fat breakdown, making weight loss harder;
• drive the ovaries to produce more androgens, worsening the hormonal picture;
• raise long-term risk of type 2 diabetes.

The hormonal environment is therefore tilted toward storage and hunger, which is why weight loss is harder in PCOS than in its absence. It also explains why treatments that improve insulin sensitivity — weight loss, activity, metformin, GLP-1 medications — tend to help several PCOS problems at once. Grade A 🟢 → Obesity & Diabetes

Androgens: the second engine

The androgen excess of PCOS produces its most visible features — acne, hirsutism, sometimes scalp hair thinning — and disrupts ovulation, causing irregular cycles and reduced fertility. Insulin resistance and excess weight worsen the androgen excess, and the androgen excess in turn reinforces the metabolic problems, so the condition behaves as a self-perpetuating loop rather than a single fault.

Because the two engines are linked, interventions rarely act on only one. Weight loss and improved insulin sensitivity can lower androgens and improve cycles and skin, while dedicated treatments such as combined hormonal contraception or anti-androgen therapy, prescribed individually, target the androgen features directly. Grade A 🟢

Weight and PCOS: harder, not impossible

Weight loss in PCOS is harder because of that metabolic environment, but the returns are large relative to the amount lost:

• Even modest loss (~5–10%) can restore more regular ovulation, improve fertility, reduce androgen symptoms and improve metabolic markers.
• The quality of loss matters: preserving muscle, through protein intake and resistance training, supports insulin sensitivity and physical function. → Exercise, Muscle & Body Composition
• The relevant measures of success are cycles, symptoms, fertility and metabolic health rather than the scale alone.
• In a woman who is already lean, weight loss is not the lever; insulin sensitivity, activity, resistance training and symptom-directed treatment remain the levers that are.

Grade A 🟢 (modest weight loss improves reproductive and metabolic outcomes in PCOS).

Fertility

PCOS often comes to attention when a woman tries to conceive, because disrupted ovulation reduces fertility. PCOS-related infertility is frequently treatable, and weight is one lever among several: improving insulin sensitivity and achieving modest weight loss can restore more regular ovulation in some women, improving both the chance of conception and the success of fertility treatment.

Two constraints apply. Weight is one contributor among many and is not a reason to withhold supportive fertility care. And where GLP-1 or GLP-1/GIP medications are used for weight, they must be stopped before trying to conceive — roughly two months before, given slow clearance — with reliable contraception while they are in use. Tirzepatide has an oral-contraceptive interaction that requires a backup or non-oral method for about 4 weeks at the start of treatment and after each dose increase, which is why medication and conception planning are coordinated together. → Women's Health & Obesity · GLP-1 & Incretin Medications

Grade B 🟡 (weight loss can improve ovulation and fertility outcomes in some women with PCOS; results vary).

Metabolic risk across the lifespan

PCOS is a lifelong metabolic condition rather than a reproductive-years problem. Women with PCOS carry higher risk of:

• Type 2 diabetes and impaired glucose tolerance, which makes periodic glucose screening worthwhile. → Obesity & Diabetes
• Cardiovascular risk factors — adverse lipids and high blood pressure.
• Metabolic-associated fatty liver disease (MASLD).
• Anxiety and depression, at higher rates than in women without PCOS. → Mental Health & Obesity

PCOS care is therefore long-term metabolic protection as much as symptom control, and the metabolic risks persist and evolve through menopause even as the reproductive features change. Grade A 🟢 → Obesity & Cardiovascular Health

The MASLD link

PCOS and metabolic-associated steatotic liver disease (MASLD) share a root in insulin resistance and visceral adiposity, so women with PCOS have a higher prevalence of fatty liver, independently of weight and amplified by it.

Fatty liver is not a single entity. The relevant questions are liver fat and fibrosis (scarring), not the presence of fat alone. In a woman with PCOS and metabolic risk factors, fibrosis-risk assessment is reasonable to consider, with FIB-4 serving as a first-line blood-based risk estimate. Grade B 🟡 → Fatty Liver / MASLD · FIB-4 Explained

Treatment: metformin, GLP-1 medications and lifestyle

Treatment is individualised to a woman's goals — cycles, fertility, hair and skin, metabolic risk, weight — and usually combines several levers.

• Lifestyle. A sustainable dietary pattern, activity and resistance training improve insulin sensitivity and preserve muscle, and modest sustained loss delivers reproductive and metabolic benefit out of proportion to its size. → Nutrition
• Metformin. An insulin-sensitising medication commonly used in PCOS to improve metabolic markers and, in some women, menstrual regularity. Its effect on weight is modest at best; it is not primarily a weight-loss drug. Grade B 🟡
• GLP-1 and GLP-1/GIP medications (semaglutide, tirzepatide). Effective for weight and metabolic health in obesity generally, and increasingly used in PCOS with obesity to reduce weight and improve insulin sensitivity, subject to the reproductive constraints above. No GLP-1 is FDA-approved for PCOS itself; all use in PCOS is off-label, targeting the associated obesity and insulin resistance rather than a distinct PCOS indication. Grade B 🟡 → GLP-1 & Incretin Medications · Obesity Medication Library
• Symptom-directed treatments. Combined hormonal contraception, anti-androgens and ovulation-induction agents for fertility target specific features and are prescribed individually.

Across all of these, treatments that improve insulin sensitivity tend to help several PCOS problems simultaneously. Grade A 🟢 → How Obesity Should Be Evaluated

Questions patients ask

Which engine dominates in a particular woman, and which combination of treatments fits her goals, is assessed individually at the practice.

Written by Darius A. Schneider, MD, PhD · Board-Certified Endocrinologist (ECNU) · Last updated: Oct 2026 · References: international evidence-based PCOS diagnostic and management guidelines; literature on insulin resistance and androgen excess in PCOS; metformin and GLP-1 evidence in PCOS and obesity; PCOS–MASLD association studies; FDA prescribing information for semaglutide and tirzepatide (pregnancy avoidance, tirzepatide oral-contraceptive interaction). No GLP-1 is FDA-approved for PCOS; such use is off-label for associated obesity/insulin resistance. Educational; not individualized medical advice.